Grapefruit / Fruit Juice Dietary Restrictions by Medication
Grapefruit / Fruit Juice Dietary Restrictions
[!danger] YES — Strict grapefruit/Seville orange restriction required
Two active medications are CYP3A4 substrates with documented grapefruit juice interactions (venetoclax, atorvastatin). Nifedipine was a third, but patient confirmed not taking nifedipine (2026-05-06). Given that posaconazole is already maximally inhibiting CYP3A4, the incremental risk from grapefruit on the remaining CYP3A4 substrates is magnified.Updated 2026-05-06: nifedipine removed from active restriction list per clinic note.
Summary Table
| Medication | Interaction | Risk | Restriction |
|---|---|---|---|
| Venetoclax | CYP3A4 substrate; GFJ ↑ levels | Toxicity (myelosuppression, TLS) | AVOID grapefruit, Seville orange, pomelo |
| Atorvastatin | CYP3A4 substrate; GFJ ↑ levels 2–3× | Myopathy / rhabdomyolysis | AVOID grapefruit |
| Nifedipine | CYP3A4 substrate; GFJ ↑ levels | ~~Excessive hypotension, edema~~ | NOT CURRENTLY ACTIVE — patient confirmed not taking nifedipine (2026-05-06). Restriction moot unless restarted. |
| Posaconazole | CYP3A4 inhibitor (not substrate); GFJ data limited | Minimal additional interaction | Avoid large quantities; precautionary |
| Losartan | CYP2C9/CYP3A4 minor; GFJ effect minimal | Negligible | No restriction needed |
| Metformin | Renally excreted; no CYP interaction | None | No restriction needed |
| Linagliptin | P-gp substrate; not CYP-dependent | None clinically significant | No restriction needed |
| Acyclovir | Renally excreted; no CYP interaction | None | No restriction needed |
Drug-by-Drug Detail
Venetoclax — AVOID grapefruit / Seville orange / pomelo
- CYP3A4 primary metabolism
- GFJ is a known CYP3A4 and P-gp inhibitor at the intestinal wall
- Standard VEN labeling: explicitly contraindicates grapefruit and Seville orange
- Context: Posaconazole already saturates systemic CYP3A4; GFJ adds intestinal CYP3A4 inhibition. Effect is additive on already-reduced metabolic clearance. Even at the dose-reduced VEN (50–100 mg), any further increase in plasma VEN → supratherapeutic levels, increased myelosuppression / TLS risk
- Also avoid: Star fruit (contains caramboxin and oxalic acid; distinct but also inhibitory), large quantities of pomelo
Atorvastatin — AVOID grapefruit
- CYP3A4 major metabolism
- GFJ ↑ atorvastatin AUC ~2.5–3.9× in studies
- Context: Posaconazole already ↑ atorvastatin ~3–5×; GFJ compounds this. Combined effect could push atorvastatin to 10–15× normal exposure. Myopathy/rhabdomyolysis risk is substantially elevated
- Not a theoretical risk — atorvastatin + strong CYP3A4 inhibitors is flagged as high-risk interaction; GFJ is an additional modifiable variable
~~Nifedipine — AVOID grapefruit~~ — NOT CURRENTLY ACTIVE (2026-05-06)
[!info] Patient confirmed not taking nifedipine as of 2026-05-06 clinic note. The grapefruit restriction for nifedipine is therefore not currently applicable. If nifedipine is restarted in the future:
- CYP3A4 primary metabolism (intestinal > hepatic)
- GFJ ↑ nifedipine AUC ~134% (one of the largest documented GFJ-drug interactions)
- Combined with posaconazole (2–3× increase) + GFJ: excessive hypotension, fall risk at age 81
- Re-impose grapefruit restriction if nifedipine is resumed.
Fruits to Avoid (All)
| Fruit | Reason |
|---|---|
| Grapefruit (any form — whole, juice, segment) | CYP3A4 intestinal inhibitor; documented drug interaction |
| Seville / bitter orange | Same CYP3A4 mechanism (furanocoumarins) |
| Pomelo (chakotara) | Same family; lower potency but same mechanism |
| Star fruit (carambola) | Distinct toxin (caramboxin); avoid in all renally-cleared drug situations |
Safe: Regular sweet orange (navel/Valencia), apple, mango, banana, papaya, pomegranate, guava — no documented CYP3A4 interactions with these.
Clinical Note
- The interaction duration after consuming grapefruit juice is 24–72 hours (irreversible CYP3A4 binding until new enzyme is synthesized)
- A single 200 mL glass of GFJ is sufficient to produce a significant interaction
- The restriction applies continuously, not just around medication dose times
- Grape juice (from Vitis vinifera) — standard grape juice does not contain furanocoumarins and has no documented CYP3A4 interaction; it is safe. The question may have intended "grapefruit juice" — clarify if grape juice was genuinely meant
Related
- Venetoclax — CYP3A4 substrate; GFJ interaction documented in prescribing information
- Atorvastatin — CYP3A4 substrate; GFJ ↑ levels 2.5–3.9×
- Nifedipine — CYP3A4 substrate; GFJ ↑ levels ~134%
- Posaconazole — Strong CYP3A4 inhibitor; ongoing context for all three interactions above
- Cyp3A4 Metabolizer Venetoclax Implications — Context on CYP3A4 pharmacokinetics in this patient